Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunGene has received a $244,479 grant under The Patient Protection and Affordable Care Act of 2010 (PPACA), related to the development of ImmunGene's technology which is based on antibody-cytokine fusions that have demonstrated targeted toxicity and added tumor benefits.
Subscribe to our email newsletter
ImmunGene’s technology empowers monoclonal antibodies targeted to tumor cells by fusing them to immune effector molecules; that is, cytokine, chemokine and co-stimulatory molecules, thereby combining the specificity of antibodies with the potent anti-tumor effects of the immune effector molecule.
ImmunGene CEO Sanjay Khare said that they are pleased that their technology platform of next generation monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders and other diseases is recognised as worthy of this development award.
"This grant will assist us in advancing our antibody-cytokine fusions that have demonstrated targeted toxicity and added tumor benefits over existing therapies through in vitro and in vivo preclinical testing," Khare said.